

# A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

NCT07220772

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Regeneron Pharmaceuticals
Enrollment	4 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Has documented medical history of biallelic loss of function variants of the LEP gene prior to the screening visit
- Has class e2 obesity at screening and at baseline, as defined in the protocol

### Exclusion (8)

- Unwilling or unable to provide, or have the treating physician provide, documented historical weight for at least 6 months prior to screening
  - History of bariatric surgery within approximately the past 12 months of study screening
  - History of weight loss of e5% of body weight in approximately the past 3 months of study screening
  - History of genetic causes of obesity other than/in addition to biallelic loss of function variants of the LEP gene
  - History of schizophrenia, bipolar disorder, or other mental illness that, in the opinion of the investigator, might pose a safety risk to participation in a clinical study of an investigational drug
- ... and 3 more (see full listing online)

## Locations (1 total)

---

ULM University Medical Centre, Ulm, Germany